Browsing Tag
NASDAQ: KALV
1 post
Investors eye KalVista’s $125m debt raise—Can EKTERLY commercialization justify the premium terms?
KalVista raises $125M through convertible notes due 2031 to fund EKTERLY commercialization. Find out what this financing means for biotech investors.